应对高于预期的呼吸道合胞病毒（RSV）导致的婴儿死亡率：改进治疗和报告策略。
Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies.
作者信息
Dvorkin Julia, De Luca Julián, Alvarez-Paggi Damian, Caballero Mauricio T
机构信息
Fundación INFANT, Buenos Aires, Argentina.
Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
出版信息
Infect Drug Resist. 2023 Jan 27;16:595-605. doi: 10.2147/IDR.S373584. eCollection 2023.
Abstract
Respiratory syncytial virus (RSV) has a major role in respiratory infections in young infants around the world. However, substantial progress has been made in recent years in the field of RSV. A wide variety of observational studies and clinical trials published in the past decade provide a thorough idea of the health and economic burden of RSV disease in the developing world. In this review, we discuss the impact of RSV burden of disease, major gaps in disease estimations, and challenges in generating new therapeutic options and an immune response against the virus, and briefly describe next generation technologies that are being evaluated.
摘要
呼吸道合胞病毒（RSV）在全球婴幼儿呼吸道感染中起主要作用。然而，近年来RSV领域已取得了重大进展。过去十年发表的大量观察性研究和临床试验，让人全面了解了RSV疾病在发展中国家造成的健康和经济负担。在本综述中，我们讨论了RSV疾病负担的影响、疾病估计中的主要差距、开发新治疗方案和针对该病毒的免疫反应所面临的挑战，并简要介绍了正在评估的下一代技术。
相似文献
1
Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies.应对高于预期的呼吸道合胞病毒（RSV）导致的婴儿死亡率：改进治疗和报告策略。
Infect Drug Resist. 2023 Jan 27;16:595-605. doi: 10.2147/IDR.S373584. eCollection 2023.
2
Respiratory Syncytial Virus Consortium in Europe (RESCEU) Birth Cohort Study: Defining the Burden of Infant Respiratory Syncytial Virus Disease in Europe.欧洲呼吸道合胞病毒联盟（RESCEU）出生队列研究：定义欧洲婴儿呼吸道合胞病毒疾病的负担。
J Infect Dis. 2020 Oct 7;222(Suppl 7):S606-S612. doi: 10.1093/infdis/jiaa310.
3
Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children.最大限度发挥预防策略对婴幼儿呼吸道合胞病毒（RSV）疾病影响的挑战。
Yale J Biol Med. 2022 Jun 30;95(2):293-300. eCollection 2022 Jun.
4
Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes.孕期接种呼吸道合胞病毒疫苗以改善婴儿结局。
Cochrane Database Syst Rev. 2024 May 2;5(5):CD015134. doi: 10.1002/14651858.CD015134.pub2.
5
Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data.2019 年导致早产儿和幼儿急性下呼吸道感染的呼吸道合胞病毒的全球疾病负担及危险因素：汇总和个体参与者数据的系统评价和荟萃分析。
Lancet. 2024 Mar 30;403(10433):1241-1253. doi: 10.1016/S0140-6736(24)00138-7. Epub 2024 Feb 14.
6
Clinical and economic burden of respiratory syncytial virus in children aged 0-5 years in Italy.意大利 0-5 岁儿童呼吸道合胞病毒的临床和经济负担。
Ital J Pediatr. 2024 Mar 25;50(1):57. doi: 10.1186/s13052-024-01628-7.
7
Burden of respiratory syncytial virus (RSV) infection in Germany: a systematic review.德国呼吸道合胞病毒（RSV）感染负担：系统评价。
BMC Infect Dis. 2024 Aug 20;24(1):844. doi: 10.1186/s12879-024-09758-3.
8
Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials.呼吸道合胞病毒，一个持续存在的医学难题：关于目前正在进行临床试验的呼吸道合胞病毒预防和治疗药物的专家评论
Influenza Other Respir Viruses. 2015 Jul;9(4):169-78. doi: 10.1111/irv.12313.
9
Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naïve infants.疫苗和相关生物制品咨询委员会会议摘要，会议旨在评估预防 RSV -naive 婴儿呼吸道合胞病毒病的候选疫苗。
Vaccine. 2020 Jan 10;38(2):101-106. doi: 10.1016/j.vaccine.2019.10.048. Epub 2019 Nov 6.
10
Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies.呼吸道合胞病毒：从发病机制到潜在的治疗策略。
Int J Biol Sci. 2021 Sep 27;17(14):4073-4091. doi: 10.7150/ijbs.64762. eCollection 2021.
引用本文的文献
1
Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participants.呼吸道合胞病毒单克隆抗体克来罗韦单抗的I期开放标签研究：中国健康受试者的安全性和耐受性
Hum Vaccin Immunother. 2025 Dec;21(1):2516948. doi: 10.1080/21645515.2025.2516948. Epub 2025 Jul 17.
2
Assessing the long-term economic impact of wheezing episodes after severe RSV disease in children from Argentina: a cost of illness analysis.评估阿根廷儿童严重呼吸道合胞病毒（RSV）疾病后喘息发作的长期经济影响：疾病成本分析。
BMJ Public Health. 2024 Jul 30;2(1):e000975. doi: 10.1136/bmjph-2024-000975. eCollection 2024 Jun.
3
Cost of illness due to respiratory syncytial virus acute lower respiratory tract infection among infants hospitalized in Argentina.因呼吸道合胞病毒急性下呼吸道感染而导致的在阿根廷住院治疗的婴儿的疾病经济负担。
BMC Public Health. 2024 Feb 10;24(1):427. doi: 10.1186/s12889-024-17878-3.
4
The Estimate of Parental Quality of Life Loss Due to Respiratory Syncytial Virus (RSV) Hospitalization.因呼吸道合胞病毒（RSV）住院导致的父母生活质量损失估计
Diseases. 2023 Sep 24;11(4):126. doi: 10.3390/diseases11040126.
本文引用的文献
1
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.呼吸道合胞病毒预防近在咫尺：疫苗和单克隆抗体领域。
Lancet Infect Dis. 2023 Jan;23(1):e2-e21. doi: 10.1016/S1473-3099(22)00291-2. Epub 2022 Aug 8.
2
Ribavirin for Treatment of Subjects with Respiratory Syncytial Virus-Related Infection: A Systematic Review and Meta-Analysis.利巴韦林治疗呼吸道合胞病毒相关感染患者的疗效：系统评价和荟萃分析。
Adv Ther. 2022 Sep;39(9):4037-4051. doi: 10.1007/s12325-022-02256-5. Epub 2022 Jul 25.
3
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.2019 年全球、区域和国家因呼吸道合胞病毒导致 5 岁以下儿童急性下呼吸道感染的疾病负担估计：系统分析。
Lancet. 2022 May 28;399(10340):2047-2064. doi: 10.1016/S0140-6736(22)00478-0. Epub 2022 May 19.
4
Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.孕期融合前 F 蛋白为基础的呼吸道合胞病毒免疫接种。
N Engl J Med. 2022 Apr 28;386(17):1615-1626. doi: 10.1056/NEJMoa2106062.
5
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.尼赛珠单抗预防健康晚期早产儿和足月婴儿 RSV 感染。
N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275.
6
EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.EDP-938，一种呼吸道合胞病毒抑制剂，在人体病毒挑战中。
N Engl J Med. 2022 Feb 17;386(7):655-666. doi: 10.1056/NEJMoa2108903.
7
Infant deaths from respiratory syncytial virus in Lusaka, Zambia from the ZPRIME study: a 3-year, systematic, post-mortem surveillance project.赞比亚卢萨卡 ZPRIME 研究：一项为期 3 年的系统尸检监测项目，导致呼吸道合胞病毒的婴儿死亡。
Lancet Glob Health. 2022 Feb;10(2):e269-e277. doi: 10.1016/S2214-109X(21)00518-0.
8
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis.正向和反向转化方法预测中和呼吸道合胞病毒 (RSV) 抗体预防效果。
EBioMedicine. 2021 Nov;73:103651. doi: 10.1016/j.ebiom.2021.103651. Epub 2021 Nov 11.
9
Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies.呼吸道合胞病毒：从发病机制到潜在的治疗策略。
Int J Biol Sci. 2021 Sep 27;17(14):4073-4091. doi: 10.7150/ijbs.64762. eCollection 2021.
10
Fatal enhanced respiratory syncytial virus disease in toddlers.幼儿致命性呼吸道合胞病毒病。
Sci Transl Med. 2021 Oct 20;13(616):eabj7843. doi: 10.1126/scitranslmed.abj7843.
Zotero 插件